Open Nav

View from the Board: Responding to an Acquisition Offer

More than 60 biopharmaceutical acquisitions of private companies took place over the past four years. One of the greatest challenges faced by a leadership team is responding to an acquisition offer. The inability to predict when such an offer is likely to be received and the deadline pressure to react quickly heighten the importance of preparing for such scenarios in advance within a board of directors. Also, the inherent tension of boards including both venture investors and managers/founders may force difficult conversations regarding valuation and risk. This panel will review how to structure those conversations and decisions to be as productive as possible.

Moderator: Michael J. O’Donnell, Partner, Morrison & Foerster LLP

  • Date:Wednesday, October 17
  • Time:4:15 PM - 5:10 PM
  • Session Type:Educational Session
Michael J. O'Donnell
Morrison & Foerster
Corey Goodman
venBio Partners
Linda Grais
Ocera Therapeutics
Nina Kjellson
Canaan Partners
Camille Samuels